Skip to main content

Peer Review reports

From: Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis

Original Submission
24 Mar 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
17 Jul 2021 Reviewed Reviewer Report
25 Jul 2021 Reviewed Reviewer Report - Kyu Shik Kim
23 Aug 2021 Author responded Author comments - Yifan Wei
Resubmission - Version 3
23 Aug 2021 Submitted Manuscript version 3
16 Oct 2021 Reviewed Reviewer Report
9 Dec 2021 Reviewed Reviewer Report - Thorgerdur Palsdottir
14 Apr 2022 Author responded Author comments - Yifan Wei
Resubmission - Version 4
14 Apr 2022 Submitted Manuscript version 4
15 Apr 2022 Author responded Author comments - Yifan Wei
Resubmission - Version 5
15 Apr 2022 Submitted Manuscript version 5
19 Apr 2022 Author responded Author comments - Yifan Wei
Resubmission - Version 6
19 Apr 2022 Submitted Manuscript version 6
Publishing
27 Apr 2022 Editorially accepted
13 May 2022 Article published 10.1186/s12894-022-01025-4

You can find further information about peer review here.

Back to article page